GammaPlus and I3 (International Isotopes) agree PET (Positron Emission Tomography) chemicals link:
This article was originally published in Clinica
Executive Summary
International Isotopes (I3) of Denton, Texas, has formed a joint venture with Austin-based GammaPlus to manufacture and distribute radiopharmaceuticals used in Positron Emission Tomography (PET). The new company, GammaPlus DFW, will distribute short-lived radiopharmaceuticals, including Fluorodeoxyglucose F-18, in Texas and other selected cities in the US. F-18 is widely used in PET whole body scans of patients with newly-diagnosed cancers, especially those of the breast and lung.
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.